2015
DOI: 10.1021/acs.jmedchem.5b01142
|View full text |Cite
|
Sign up to set email alerts
|

Structural Dissection of Crotalicidin, a Rattlesnake Venom Cathelicidin, Retrieves a Fragment with Antimicrobial and Antitumor Activity

Abstract: In silico dissection of crotalicidin (Ctn), a cathelicidin from a South American pit viper, yielded fragments Ctn[1-14] and Ctn[15-34], which were tested to ascertain to what extent they reproduced the structure and activity of the parent peptide. NMR data showing Ctn to be α-helical at the N-terminus and unstructured at the C-terminus were matched by similar data from the fragments. The peptides were tested against Gram-positive and -negative bacteria and for toxicity against both tumor and healthy cells. Des… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

11
96
0

Year Published

2017
2017
2020
2020

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 66 publications
(107 citation statements)
references
References 60 publications
11
96
0
Order By: Relevance
“…Sequences of Ctn [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34] and analogs were submitted to the PSIPRED v3.3 (http://bioinf.cs.ucl.ac.uk/psipred/) 38 web server to predict secondary structure propensity. For 3D structure prediction, the PEP-FOLD3 web server (http://bioserv.rpbs.univ-paris-diderot.fr/services/ PEP-FOLD3/#usage) 39 was accessed, and the best five models (lowest OPEP [optimized potential for efficient structure prediction] energy) were superposed and represented using the PyMOL Molecular Graphical System, Version 2.0.…”
Section: Simulation Of Peptide Structurementioning
confidence: 99%
“…Sequences of Ctn [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34] and analogs were submitted to the PSIPRED v3.3 (http://bioinf.cs.ucl.ac.uk/psipred/) 38 web server to predict secondary structure propensity. For 3D structure prediction, the PEP-FOLD3 web server (http://bioserv.rpbs.univ-paris-diderot.fr/services/ PEP-FOLD3/#usage) 39 was accessed, and the best five models (lowest OPEP [optimized potential for efficient structure prediction] energy) were superposed and represented using the PyMOL Molecular Graphical System, Version 2.0.…”
Section: Simulation Of Peptide Structurementioning
confidence: 99%
“…Good agreement between the proposed NMR and predicted structures was also found for longer peptides that showed clear curvature in the proposed experimental structure, for example magainin-2 (PDB: 2MAG [68]), crotalicidin (PDB: 2MWT [85]) and LL-37 (PDB: 2K6O [89]). Again in a number of cases, the predicted structures showed greater curvature than that proposed based on the NMR data, especially at low mutation rates, for example LL-23 (PDB: 2LMF [67]) and CAP18 (PDB: 1LYP [87]).…”
Section: Validation and Testing Of The Asp Algorithmmentioning
confidence: 66%
“…The ASP algorithm was run with different values of the key parameters (hydrophobic scale, tournament size, and torsion mutation rate) on a selected subset of the systems in Table . The subset consisted of alyteserin‐1c (PDB: http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2L5R ), CAP18 (PDB: http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1LYP ), crotalicidin (PDB: http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2MWT ), GF‐17 (PDB: http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2L5M ), hylin a1 (PDB: http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2N0O ) and LL‐37 (PDB: http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2K6O ). These systems were selected so as to represent a range of sizes as well as linear and curved helices.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…These peptides show potent broad spectrum activity against microorganisms that include Gram-negative and Gram-positive bacteria, enveloped viruses, fungi and even cancerous cells and display potential for their future development as novel therapeutic agents345678910.…”
mentioning
confidence: 99%